Biogen

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Roche starts new four-year trial of Alzheimer's drug gantene...

With prospects of an early, accelerated approval for Roche's Alzheimer's disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the hope of b

News

Sage, Biogen's zuranolone looks approvable, but will it sell...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response.

News

Eisai bites back against restricted coverage plan for Aduhel...

Japanese drugmaker Eisai has published comments filed with the US Centers for Medicare & Medicaid Services over its restrictive coverage proposal for beleaguered Alzheimer's drug Aduhel

News

Lilly defers Alzheimer's drug filing after CMS' 'disappointi...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has

News

Biogen's former R&D chief Al Sandrock resurfaces at Voyager

Al Sandrock's shock departure from Biogen in November sparked speculation about where he would show up next, and the answer came in today – gene therapy specialist Voyager Therapeutics.

News